nodes	percent_of_prediction	percent_of_DWPC	metapath
Dicyclomine—CYP1A1—Thalidomide—leprosy	0.753	1	CbGbCtD
Dicyclomine—Complex regional pain syndrome—Thalidomide—leprosy	0.0731	0.296	CcSEcCtD
Dicyclomine—Thrombosis—Thalidomide—leprosy	0.00622	0.0252	CcSEcCtD
Dicyclomine—Muscular weakness—Dapsone—leprosy	0.00551	0.0223	CcSEcCtD
Dicyclomine—Tingling sensation—Thalidomide—leprosy	0.00548	0.0222	CcSEcCtD
Dicyclomine—Numbness—Thalidomide—leprosy	0.00531	0.0215	CcSEcCtD
Dicyclomine—Apnoea—Thalidomide—leprosy	0.00519	0.021	CcSEcCtD
Dicyclomine—Sensory loss—Thalidomide—leprosy	0.00508	0.0206	CcSEcCtD
Dicyclomine—Dyskinesia—Thalidomide—leprosy	0.00469	0.019	CcSEcCtD
Dicyclomine—Lightheadedness—Thalidomide—leprosy	0.00394	0.016	CcSEcCtD
Dicyclomine—Erythema—Dapsone—leprosy	0.00376	0.0152	CcSEcCtD
Dicyclomine—Thrombophlebitis—Thalidomide—leprosy	0.00369	0.015	CcSEcCtD
Dicyclomine—Vision blurred—Dapsone—leprosy	0.00354	0.0144	CcSEcCtD
Dicyclomine—Amnesia—Thalidomide—leprosy	0.0034	0.0138	CcSEcCtD
Dicyclomine—Lethargy—Thalidomide—leprosy	0.00326	0.0132	CcSEcCtD
Dicyclomine—Diplopia—Thalidomide—leprosy	0.0032	0.0129	CcSEcCtD
Dicyclomine—Affect lability—Thalidomide—leprosy	0.00315	0.0127	CcSEcCtD
Dicyclomine—Face oedema—Thalidomide—leprosy	0.00309	0.0125	CcSEcCtD
Dicyclomine—Mood swings—Thalidomide—leprosy	0.00303	0.0123	CcSEcCtD
Dicyclomine—Tachycardia—Dapsone—leprosy	0.003	0.0121	CcSEcCtD
Dicyclomine—Breast disorder—Thalidomide—leprosy	0.00289	0.0117	CcSEcCtD
Dicyclomine—Muscular weakness—Thalidomide—leprosy	0.00282	0.0114	CcSEcCtD
Dicyclomine—Abdominal distension—Thalidomide—leprosy	0.00278	0.0113	CcSEcCtD
Dicyclomine—Insomnia—Dapsone—leprosy	0.00278	0.0112	CcSEcCtD
Dicyclomine—Erectile dysfunction—Thalidomide—leprosy	0.00254	0.0103	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Dapsone—leprosy	0.00251	0.0102	CcSEcCtD
Dicyclomine—Drowsiness—Thalidomide—leprosy	0.00246	0.00998	CcSEcCtD
Dicyclomine—Abdominal pain—Dapsone—leprosy	0.00243	0.00983	CcSEcCtD
Dicyclomine—Hypoaesthesia—Thalidomide—leprosy	0.0022	0.00891	CcSEcCtD
Dicyclomine—Eye disorder—Thalidomide—leprosy	0.00207	0.00837	CcSEcCtD
Dicyclomine—Cardiac disorder—Thalidomide—leprosy	0.00205	0.00831	CcSEcCtD
Dicyclomine—Immune system disorder—Thalidomide—leprosy	0.002	0.00809	CcSEcCtD
Dicyclomine—Mediastinal disorder—Thalidomide—leprosy	0.00199	0.00807	CcSEcCtD
Dicyclomine—Vomiting—Dapsone—leprosy	0.00195	0.0079	CcSEcCtD
Dicyclomine—Mental disorder—Thalidomide—leprosy	0.00194	0.00785	CcSEcCtD
Dicyclomine—Headache—Dapsone—leprosy	0.00192	0.00779	CcSEcCtD
Dicyclomine—Tension—Thalidomide—leprosy	0.00189	0.00765	CcSEcCtD
Dicyclomine—Nervousness—Thalidomide—leprosy	0.00187	0.00757	CcSEcCtD
Dicyclomine—Nausea—Dapsone—leprosy	0.00182	0.00738	CcSEcCtD
Dicyclomine—Vision blurred—Thalidomide—leprosy	0.00181	0.00735	CcSEcCtD
Dicyclomine—Ill-defined disorder—Thalidomide—leprosy	0.00179	0.00724	CcSEcCtD
Dicyclomine—Agitation—Thalidomide—leprosy	0.00177	0.00717	CcSEcCtD
Dicyclomine—Angioedema—Thalidomide—leprosy	0.00176	0.00713	CcSEcCtD
Dicyclomine—Malaise—Thalidomide—leprosy	0.00174	0.00703	CcSEcCtD
Dicyclomine—Syncope—Thalidomide—leprosy	0.00173	0.00699	CcSEcCtD
Dicyclomine—Palpitations—Thalidomide—leprosy	0.0017	0.00689	CcSEcCtD
Dicyclomine—Loss of consciousness—Thalidomide—leprosy	0.00169	0.00685	CcSEcCtD
Dicyclomine—Hypertension—Thalidomide—leprosy	0.00166	0.00673	CcSEcCtD
Dicyclomine—Discomfort—Thalidomide—leprosy	0.00162	0.00656	CcSEcCtD
Dicyclomine—Dry mouth—Thalidomide—leprosy	0.0016	0.00649	CcSEcCtD
Dicyclomine—Confusional state—Thalidomide—leprosy	0.00158	0.00642	CcSEcCtD
Dicyclomine—Oedema—Thalidomide—leprosy	0.00157	0.00636	CcSEcCtD
Dicyclomine—Shock—Thalidomide—leprosy	0.00155	0.00626	CcSEcCtD
Dicyclomine—Nervous system disorder—Thalidomide—leprosy	0.00154	0.00624	CcSEcCtD
Dicyclomine—Tachycardia—Thalidomide—leprosy	0.00153	0.00621	CcSEcCtD
Dicyclomine—Anorexia—Thalidomide—leprosy	0.0015	0.00607	CcSEcCtD
Dicyclomine—Insomnia—Thalidomide—leprosy	0.00142	0.00576	CcSEcCtD
Dicyclomine—Paraesthesia—Thalidomide—leprosy	0.00141	0.00571	CcSEcCtD
Dicyclomine—Dyspnoea—Thalidomide—leprosy	0.0014	0.00567	CcSEcCtD
Dicyclomine—Somnolence—Thalidomide—leprosy	0.0014	0.00566	CcSEcCtD
Dicyclomine—Dyspepsia—Thalidomide—leprosy	0.00138	0.0056	CcSEcCtD
Dicyclomine—Decreased appetite—Thalidomide—leprosy	0.00137	0.00553	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Thalidomide—leprosy	0.00136	0.00549	CcSEcCtD
Dicyclomine—Fatigue—Thalidomide—leprosy	0.00135	0.00549	CcSEcCtD
Dicyclomine—Pain—Thalidomide—leprosy	0.00134	0.00544	CcSEcCtD
Dicyclomine—Constipation—Thalidomide—leprosy	0.00134	0.00544	CcSEcCtD
Dicyclomine—Feeling abnormal—Thalidomide—leprosy	0.00129	0.00524	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Thalidomide—leprosy	0.00128	0.0052	CcSEcCtD
Dicyclomine—Urticaria—Thalidomide—leprosy	0.00125	0.00506	CcSEcCtD
Dicyclomine—Abdominal pain—Thalidomide—leprosy	0.00124	0.00503	CcSEcCtD
Dicyclomine—Hypersensitivity—Thalidomide—leprosy	0.00116	0.00469	CcSEcCtD
Dicyclomine—Asthenia—Thalidomide—leprosy	0.00113	0.00457	CcSEcCtD
Dicyclomine—Pruritus—Thalidomide—leprosy	0.00111	0.0045	CcSEcCtD
Dicyclomine—Dizziness—Thalidomide—leprosy	0.00104	0.00421	CcSEcCtD
Dicyclomine—Vomiting—Thalidomide—leprosy	0.000999	0.00405	CcSEcCtD
Dicyclomine—Rash—Thalidomide—leprosy	0.000991	0.00401	CcSEcCtD
Dicyclomine—Dermatitis—Thalidomide—leprosy	0.00099	0.00401	CcSEcCtD
Dicyclomine—Headache—Thalidomide—leprosy	0.000984	0.00399	CcSEcCtD
Dicyclomine—Nausea—Thalidomide—leprosy	0.000933	0.00378	CcSEcCtD
